This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

JAMA. 2000;284:33.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved OxiFirst Fetal Oxygen Saturation Monitoring System (Mallinckrodt/Nellcor, Pleasanton, Calif), the first pulse oximeter for continuous monitoring of intrapartum fetal oxygen saturation (FSpO₂). Use of the OxiFirst system is indicated as an adjunct to fetal heart rate (FHR) monitoring in the presence of a nonreassuring fetal heart rate pattern and for a singleton fetus in vertex presentation with a gestational age of at least 36 weeks. The system consists of an intrauterine sensor, a connecting cable, and a patient monitor.

When a nonreassuring FHR pattern is observed, the sensor may be inserted after adequate cervical dilation and membrane rupture and placed against the fetus's cheek or temple. Bench, animal, and neonatal studies have demonstrated system accuracy for a single oxygenation reading of approximately 5%. The system more accurately reflects the true oxygenation status of the fetus (0.6% difference between arterial oxygen saturation and SpO₂ when tested . . . [Full Text of this Article]